Features of Japanese Patients with Myelodysplastic Syndrome in an Aging Population of Sado Island

Overview

Journal Int J Hematol

Specialty Hematology

Date 2012 Feb 25

PMID 22362009

Authors

Kumiko Yagisawa

Kiyoshi Okazuka

Ken Toba

Masaru Urushiyama

Takashi Kuroha

Noriko Izumi

Yasuhiko Sibasaki

Masutaka Higashimura

Toshio Yano

Akihito Momoi

Akira Hattori

Ken Momotsu

Yoshifusa Aizawa

Affiliations

Soon will be listed here.

Abstract

Myelodysplastic syndrome (MDS) is relatively common in the elderly, and aging of populations is progressing in developed nations, notably so in Japan. The major age group in Japan and Sado Island are distributed between 30 and 60 and between 50 and 80, respectively. The aim of this study was to analyze the features of MDS in the population of Sado Island to anticipate the characteristics of the disease in the near future. One-hundred and fifty-three patients (71 male, 82 female, 19-94 years old, median 73 years old) with de novo MDS between 1985 and 2005 were retrospectively evaluated. All patients were reclassified according to WHO-2001 criteria. The predictive power of the international prognostic scoring system and the WHO classification-based prognostic scoring system were evaluated. The major causes of death were leukemic transformation (38%) in refractory anemia with an excess of blasts and infection (48%) for total MDS. Age was another independent prognostic factor. Elderly patients exhibited a significantly poorer prognosis mainly due to infections such as pneumonia. Although novel remedies for MDS and hyperferremia have recently been developed, prevention of infection remains important in MDS, particularly for older patients.

References

Li L, Liu X, Nie L, Yu M, Zhang Y, Qin T . Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. Leuk Res. 2009; 33(9):1194-8. DOI: 10.1016/j.leukres.2008.11.021. View

Pomeroy C, Oken M, RYDELL R, Filice G . Infection in the myelodysplastic syndromes. Am J Med. 1991; 90(3):338-44. View

Van Den Berghe H, Cassiman J, David G, Fryns J, Michaux J, SOKAL G . Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974; 251(5474):437-8. DOI: 10.1038/251437a0. View

Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S . Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood. 2005; 106(8):2633-40. DOI: 10.1182/blood-2005-01-0040. View

Horiike S, Misawa S, Kaneko H, Kobayashi M, Nakao M, Nakagawa H . International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol. 2001; 115(2):309-12. DOI: 10.1046/j.1365-2141.2001.03073.x. View

Breccia M, Federico V, Latagliata R, Mercanti C, DElia G, Cannella L . Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res. 2010; 35(2):159-62. DOI: 10.1016/j.leukres.2010.06.005. View

Radlund A, THIEDE T, Hansen S, Carlsson M, Engquist L . Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol. 1995; 54(3):153-6. DOI: 10.1111/j.1600-0609.1995.tb00206.x. View

Oguma S, Yoshida Y, Okuma M, Uchino H, Maekawa T, Nomura T . Mode of disease progression in primary myelodysplastic syndromes: a Japanese co-operative study. The Refractory Anemia Study Group of The Ministry of Health and Welfare, Japan. Leuk Res. 1997; 21(3):241-7. DOI: 10.1016/s0145-2126(96)00120-8. View

List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E . Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355(14):1456-65. DOI: 10.1056/NEJMoa061292. View

10.

Iwanaga M, Hsu W, Soda M, Takasaki Y, Tawara M, Joh T . Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2010; 29(4):428-34. DOI: 10.1200/JCO.2010.31.3080. View

11.

Raza A, Reeves J, Feldman E, Dewald G, Bennett J, Deeg H . Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2007; 111(1):86-93. DOI: 10.1182/blood-2007-01-068833. View

12.

Kantarjian H, OBrien S, Ravandi F, Cortes J, Shan J, Bennett J . Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113(6):1351-61. PMC: 4188533. DOI: 10.1002/cncr.23697. View

13.

Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88. View

14.

Park M, Kim H, Kim S, Kim D, Kim S, Jang J . Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol. 2008; 81(5):364-73. DOI: 10.1111/j.1600-0609.2008.01124.x. View

15.

Nosslinger T, Tuchler H, Germing U, Sperr W, Krieger O, Haase D . Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol. 2009; 21(1):120-5. DOI: 10.1093/annonc/mdp264. View

16.

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

17.

Alessandrino E, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato L . Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002; 87(12):1286-306. View

18.

Tasaka T, Tohyama K, Kishimoto M, Ohyashiki K, Mitani K, Hotta T . Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. Leukemia. 2008; 22(10):1874-81. DOI: 10.1038/leu.2008.199. View

19.

Della Porta M, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C . Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2008; 27(5):754-62. DOI: 10.1200/JCO.2008.18.2246. View

20.

Williamson P, Kruger A, Reynolds P, Hamblin T, Oscier D . Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994; 87(4):743-5. DOI: 10.1111/j.1365-2141.1994.tb06733.x. View